Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective diligently but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past few shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire employment interview which I came away with a bad viewpoint of the company.

Irony of irony, my poor opinion of the company has grown steadily, although the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the technology and connected intellectual property from Progenics to CytoDyn, and roughly 25 million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) along with the first new drug application endorsement ($five million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and numerous therapies, it’s this individual treatments and a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an active company with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple publications in addition to multiple presentations.

Could all of it be smoke and mirrors? That is a question I’ve been asking myself through the very start of my interest in this organization. Judging by way of the multiples of thousands of several commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or even some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *